New study shows benefit of early therapy in HIV-infected infantsAntiretroviral therapy (ART) for infants born with HIV infection may be most effective when given in their first five months of life, according to a study published in the April 1 issue of The Journal of Infectious Diseases, now available online.
Uncertainty over when to start antiretroviral treatment in children infected with HIV from their mothers revolves around balancing the benefits of preventing disease progression and the risks and costs of life-long therapy begun within months of birth. Policies on when to start ART vary across Europe. Up to this point, the effect of age on clinical outcome has been difficult to assess because CD4 cell counts--an immunological indicator of HIV progression--experience considerable age-related variation.
However, Marie-Louise Newell, MD, and her colleagues in the European Collaborative Study developed a way to standardize CD4 cell counts in relation to age, and thus better evaluate immune status. They call this age-adjusted CD4 cell count the "z-score." Based on data collected over the past 20 years on infected children born to HIV-1 infected women, the investigators concluded that "children who started their most potent ART between 5 months and 5 years of age were almost 60 percent less likely to attain a 20 percent increase in their CD4 cell count z-score at any time, compared to children who started treatment before 5 months."
However, the authors did not find an association between early age at initiation and an increased likelihood of sustaining CD4 cell level recovery. They found that the risk of subsequent deterioration was similar for children initiating treatment in all age groups.
Still, because initiating effective antiretroviral therapy before 5 months of age was strongly associated with more rapid improvement in CD4 cell count, the authors conclude it should be strongly considered in the management of infants infected with HIV.
The authors declared they had no conflicts of interest to disclose.
Founded in 1904, The Journal of Infectious Diseases is the premier publication in the Western Hemisphere for original research on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune mechanisms. Articles in JID include research results from microbiology, immunology, epidemiology, and related disciplines. JID is published under the auspices of the Infectious Diseases Society of America (IDSA). Based in Alexandria, Va., IDSA is a professional society representing about 8,000 physicians and scientists who specialize in infectious diseases. For more information, visit www.idsociety.org.
Published on PsychCentral.com. All rights reserved.